Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Governance document

Draft conflicts-of-interest policy

Consultation on the policy governing the declaration and management of interests across the Institute, covering assessment committee members, external reviewers, contributors and respondents to consultations. The draft proceeds from the position that a…

Document identifier
CEI-CP-010
Series
Public comment period
Version
1.0
Published
01 Apr 2023
Last reviewed
01 Apr 2023
Next review
01 Apr 2024
Identifier
10.71829/cei.cp.10
Certainty
Not rated
Cycle
2023 Q1
Window
26 Jan 2023 – 23 Mar 2023
Status
Closed
Submissions
12

§1Consultation and window

§1.1Window

Opened
26 January 2023
Closed
23 March 2023
Duration
56 days
Status
Closed — the disposition is published
Document under consultation
Governance document
Submissions received
12

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Should an industry submission be identified as such on its face, or is publication of the declared interest sufficient?
  2. Is the materiality threshold for a shareholding set at a level that captures the holdings a reader would consider relevant?
  3. Should recusal be automatic on any declared financial interest, or determined case by case against the specific document?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The policy was ratified with amendments. Every respondent who addressed the first question supported identifying an industry submission on its face, and that requirement now applies across the consultation record. Recusal remains determined against the specific document rather than applied automatically.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.